Journal of Circulating Biomarkers

Circulating biomarkers, diagnostics using protein and lipid markers, exosomes, microvesicles, from basic science to translational and clinical applications. Circulating biomarkers, diagnostics using protein and lipid markers, exosomes, microvesicles, from basic science to translational and clinical applications.


Journal of Circulating Biomarkers is an international, peer-reviewed, open access, scientific, online only journal, published once a year. It focuses on all aspects of the rapidly growing field of circulating blood-based biomarkers and diagnostics using circulating protein and lipid markers, circulating tumor cells (CTC), circulating cell-free DNA (cfDNA) and extracellular vesicles, including exosomes, microvesicles, microparticles, ectosomes and apoptotic bodies. The journal publishes high-impact articles that deal with all fields related to circulating biomarkers and diagnostics, ranging from basic science to translational and clinical applications. Papers from a wide variety of disciplines are welcome; interdisciplinary studies are especially suitable for this journal. 

Included within the scope are a broad array of specialties including (but not limited to) cancer, immunology, neurology, metabolic diseases, cardiovascular medicine, regenerative medicine, nosology, physiology, pathology, technological applications in diagnostics, therapeutics, vaccine, drug delivery, regenerative medicine, drug development and clinical trials. The journal also hosts reviews, perspectives and news on specific topics.


All submitted articles considered suitable for Journal of Circulating Biomarkers are subjected to rigorous peer review to ensure the highest levels of quality. The review process is carried out as quickly as possible to minimize any delays in the online publication of articles.  This journal publishes new articles as soon as they are ready for publication (online first, as customary now for scientific journals) and then collecteding them in an issue, to guarantee rapid and efficient publication times and a content distribution to its indexing databases.


Submissions are encouraged from all institutions and on all topics related to circulation protein and lipid markers, CTC, cfDNA and extracellular vesicles, including: 

  • technical development and clinical application of circulating protein and lipid markers
  • technical advances in isolation, purification and characterization of CTC, cfDNA, exosomes and other extracellular vesicles
  • clinical applications of CTCs, circulating cell free DNA and extracellular vesicles
  • use of CTCs, cfDNA, exosomes and extracellular vesicles in diagnostics and companion diagnostics
  • use of extracellular vesicles in therapeutics delivery, antigen presentation and vaccine development
  • design and production of cell-derived vesicles and synthetic vesicles
  • biogenesis of extracellular vesicles, both in eukaryotic and prokaryotic cells
  • mechanisms of vesicle: cell interactions intercellular signaling
  • intercellular traffic of proteins, nucleic acids and other macromolecules
  • modulation of the extracellular matrix
  • roles of extracellular vesicles in normal physiological processes, including differentiation, development, immunity, tissue repair, stem cell biology, etc.
  • roles of extracellular vesicles in disease, including cancer, neurodegeneration, diabetes, chronic inflammatory diseases, cardiovascular diseases, infectious disease, ageing, etc.
  • virology and bacteriology
  • use of extracellular vesicles in association with other synthetic nanoparticle for different scopes

See Abstracting and Indexing here.



Editor in Chief

Luis Zerbini | International Centre for Genetic Engineering and Biotechnology (ICGEB), Cape Town - South Africa


Former Editor

Winston Kuo | Prophet Genomics, San José - USA
Former Assistant Professor, Harvard School of Dental Medicine, Department of Developmental Biology, and founder and former Director of Harvard Medical School, Harvard Catalyst - Laboratory for Innovative Translational Technologies


Associate Editors

Roger Chammas | Universidade de Sao Paulo, Department of Radiology and Oncology | Sao Paulo - Brazil
Alain Charest | Harvard University, Beth Israel Deaconess Medical Center | Boston - USA
Clark Chen | UC San Diego Medical Center, Division of Neurosurgery | San Diego - USA
Stefano Fais |  Istituto Superiore di Sanità (National Institute of Health), Department of Drug Research and Medicine Evaluationy | Rome - Italy
Ionita Ghiran | Harvard Medical School, Beth Israel Deaconess Medical Center | Boston - USA
Nancy Raab-Traub | University of North Carolina, Department of Microbiology and Immunology | Chapel Hill - USA
Lawrence Rajendran | University of Zurich, Systems and Cell Biology of Neurodegeneration | Zurich - Switzerland
John Sinden | ReNeuron, Chief Scientific Officer | Bridgend - UK
Johan Skog | Exosome Diagnostics, Chief Scientific Officer | Cambridge - USA
Alexander Vlassov | Thermo Fisher Scientific, Research & Development | Austin - USA
David T. Wong | University of California Los Angeles, Department of Dentistry | Los Angeles - USA 


Editorial Board Members

Angel Ayuso-Sacido | University of California Los Angeles, Department of Dentistry | Madrid - Spain
Leonora Balaj | Massachusetts General Hospital, Neurology | Charlestown - USA
Pauline Carnell-Morris | Malvern Instruments, Senior Application Scientist | Amesbury - UK
Cesar Castro | Harvard Medical School, Cancer Theranostics Program, MGH Center for Systems Biology | Boston - USA
Chih Chen | National Tsinghua University, Institute of Nanoengineering and Microsystems | Hsinchu - China
William Cho | Queen Elizabeth Hospital, Hong Kong - Hong Kong
Pui-Wah Choi | Harvard Medical School, Department of Obstetrics/Gynecology and Reproductive Biology, Brigham and Women's Hospital | Hong Kong
Emanuele Cocucci | Ohio State University, Division of Pharmaceutics and Pharmaceutical Chemistry, College of Pharmacy | Columbus - USA
Utkan Demirci | Stanford School of Medicine , Radiology  | Standford - USA
Dolores Di Vizio | UCLA, Cedars-Sinai Medical Center | Los Angeles - USA
Jiang He | University of Virginia, Department of Radiology and Medical Imaging | Charlottesville - USA
Stefano Holdenrieder | University of Munich, Deutsches Herzzentrum Munchen | Munich - Germany
Bo Huang | Tongji Medical College, Biochemistry and Molecular Biology | Huazhong - China
Takanori Ichiki | The University of Tokyo, Department of Materials Engineering | Tokyo - Japan
Alexander Ivanov | Northeastern University, Dept. of Chemistry and Chemical Biology | Boston - USA
Won Jong Rhee | Incheon National University, Division of Bioengineering | Incheon - South Korea
Mehmet Kesimer | The University of North Carolina at Chapel Hill, Mehmet Kesimer Research laboratory  | Chapel Hill - USA
Miroslaw Kornek | Saarland University Medical Center, Department of Medicine II | Homburg - Germany
Masahiko Kuroda | Tokyo Medical University, Molecular Pathology | Tokyo - Japan
Heedoo Lee | Changwon National University, Department of Biology and Chemistry | Changwon - South Korea
Marcis Leja | University of Latvia, Riga East University hospital | Riga  - Latvia
Sai-Kiang Lim | Institute of Medical Biology, Exosome and Secreted Nanovesicle | Singapore - Singapore
Aija Line | Latvian Biomedical Research and Study Centre, Cancer Biomarker group | Riga - Latvia
Jan Lotvall | University of Gothenberg, Department of Internal Medicine | Gothenburg - Sweden
Todd Lowe | University of California, Santa Cruz, Dept. of Biomolecular Engineering, | Santa Cruz - USA
Pierre-Yves Mantel | University of Fribourg, Unit of Anatomy  | Fribourg - Switzerland
David G. Meckes | Florida State University, Department of Biomedical Sciences | Tallahassee - USA
Andreas Moller | QIMR Berghofer Medical Research Institute, Tumour Microenvironment Laboratory | Brisbane - Australia
Fatemeh Momen-Heravi | Columbia University, Herbert Irving Comprehensive Cancer Center | New York - USA
Shannon Pendergrast | Ymir Genomics LLC, 700 Main Street, | Cambridge - USA
Eva Rohde | University Hospital Salzburg, Department of Serology and Blood Transfusion | Salzburg - Austria
Shivani Sharma | University of California, Los Angeles, California Nanosystems Institute | Los Angeles - USA
Kiyotaka Shiba | Japanese Foundation for Cancer Research, Division of Protein Engineering, Cancer Institute | Tokyo - Japan
Yoshinobu Takakura | Kyoto University, Department of Biopharmaceutics and Drug Metabolism, Graduate School of Pharmaceutical Sciences | Kyoto - Japan
Yaoliang Tang | Augusta University, Dept. of Medicine | Georgia - USA
John Tigges | Beth Israel Deaconess Medical Center, Flow Cytometry Science Center | Boston - USA
Matt Trau | The University of Queensland, Centre for Personalised Nanomedicine, Australian Institute for Bioengineering and Nanotechnology | Queensland - Australia
Jody Vykoukal | The University of Texas MD Anderson Cancer Center, McCombs Institute for the Early Detection and Treatment of Cancer | Houston - USA
ShuQi Wang | Zhejiang University, State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, First Affiliated Hospital | Hangzhou - China
Gareth Willis | Boston Children's Hospital, Devision of newborn medicine | Boston - USA
Matthew J. Wood | University of Oxford, Department of physiology, Anatomy and Genetics | Oxford  - UK
Cynthia Yamamoto | Hitachi Chemical Co, R and D Center | Irvine - USA
Milis Yuana | University Medical Centre Utrecht, Imaging Division, Image Sciences Institute | Utrecht - Netherlands
Huang-ge Zhang | University of Louisville Medical School, Department of Microbiology & Immunology | Louisville - USA
Davide Zocco | Exosomics, Molecular Diagnostics  | Siena - Italy



AboutScience is an open access multidisciplinary publisher based in Milan (Italy) which receives no public or educational funding, focused on clinical medicine and healthcare in its broadest term, including digital innovation, health technology assessment, narrative medicine, patient engagement, public involvement and other topics of growing impact.

We consider, review and publish observations that are critical for the advancement of our knowledge and we offer equal opportunity for all authors to publish their research. We have implemented a rigorous peer-review process and apply strict ethical policies to ensure high quality contributions across diverse fields. We screen submitted contents with iThenticate to ensure originality and work with ReviewerCredits to provide our reviewers credits for their contribuiton.

We provide the highest editorial standards with a simplified and cost-effective submission process to ensure efficient dissemination of accepted content.

Find out more on AboutScience here.



Articles submitted to Journal of Circulating Biomarkers (JCB) are published after having successfully completed the peer-review process. The publication of open access articles is covered by an Article Processing Charge (APC) paid by the author after acceptance. There are no submission fees, no fees for rejected articles and there is no additional cost for manuscript length, colour items or supplementary files, including videos. APC is waived for invited reviews and editorials.

Readers have unlimited access to the full text of all articles published in the journal, without subscription or other firewalls, with no embargo period. Open Access contents are therefore more effectively included in search engines and indexing databases, resulting in larger visibility and higher citation. Authors contributing to DTI agree to publish their articles under the Creative Commons Attribution Non-Commercial CC-BY-NC 4.0 (CC-BY-NC 4.0) license, which allows third parties to re-use the work without permission as long as the work is properly referenced and the use is non-commercial. Re-use for commercial purposes is not permitted.


To request permission or to establish permitted uses contact our permission office.

Manuscripts funded by the Wellcome Trust, RCUK, and other organizations with the same requirements, Open Access papers are published under the Creative Common Attribution 4.0 International (CC BY 4.0) which allows users to:

  • copy and redistribute the material in any medium or format
  • remix, transform, and build upon the material for any purpose, even commercially.

For additional information on our open access policy, please contact us.


Collection Information